Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study (GQS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00963144
First received: August 12, 2009
Last updated: October 20, 2010
Last verified: October 2010

August 12, 2009
October 20, 2010
July 2009
November 2009   (final data collection date for primary outcome measure)
To determine the applicability and utility of Gerd Q in the diagnosis of GERD and assessment of treatment response [ Time Frame: The applicability and utility of the Gerd Questionnaire will be done on 2 vists- Day 1 and Day 30 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00963144 on ClinicalTrials.gov Archive Site
To assess and monitor the treatment response of patients diagnosed with GERD [ Time Frame: The monitoring and assessment of treatment response using the Gerd Questionnaire will be done on 2 vists-Day 1 and Day 30 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study
Diagnosis and Response to Treatment Using a Reliable Gerd Questionnaire-an In Clinical Practise Study

The purpose of the study is to determine the applicability and utility of Gerd Q in the diagnosis of GERD and in the assessment of treatment response.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Primary care clinic

Gastroesophageal Reflux Disease
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
250
November 2009
November 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients of either gender aged between 18-79 years of age
  • Patients must be having symptoms of gastroesophageal reflux disease

Exclusion Criteria:

  • None
Both
18 Years to 79 Years
No
Contact information is only displayed when the study is recruiting subjects
Malaysia
 
NCT00963144
NIS-GMY-DUM-2009/1
No
AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Goh Khean Lee, MBBS, MRCP, FRCP Faculty of Medicine, University of Malaya Medical Center (UMMC),
AstraZeneca
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP